AR066063A1 - Derivados de triazol que son antagonistas de smo - Google Patents

Derivados de triazol que son antagonistas de smo

Info

Publication number
AR066063A1
AR066063A1 ARP080101540A ARP080101540A AR066063A1 AR 066063 A1 AR066063 A1 AR 066063A1 AR P080101540 A ARP080101540 A AR P080101540A AR P080101540 A ARP080101540 A AR P080101540A AR 066063 A1 AR066063 A1 AR 066063A1
Authority
AR
Argentina
Prior art keywords
compound
solvate
pharmaceutically acceptable
acceptable salt
cancer
Prior art date
Application number
ARP080101540A
Other languages
English (en)
Spanish (es)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR066063A1 publication Critical patent/AR066063A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP080101540A 2007-04-18 2008-04-15 Derivados de triazol que son antagonistas de smo AR066063A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92501807P 2007-04-18 2007-04-18

Publications (1)

Publication Number Publication Date
AR066063A1 true AR066063A1 (es) 2009-07-22

Family

ID=39433852

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101540A AR066063A1 (es) 2007-04-18 2008-04-15 Derivados de triazol que son antagonistas de smo

Country Status (12)

Country Link
US (1) US7691887B2 (enExample)
EP (1) EP2136803B1 (enExample)
JP (1) JP5498936B2 (enExample)
CN (1) CN101663033B (enExample)
AR (1) AR066063A1 (enExample)
AT (1) ATE555785T1 (enExample)
AU (1) AU2008241527B2 (enExample)
CA (1) CA2683946C (enExample)
CL (1) CL2008001074A1 (enExample)
PE (1) PE20090806A1 (enExample)
TW (1) TW200901987A (enExample)
WO (1) WO2008130552A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
PE20091180A1 (es) * 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
ES2610130T3 (es) 2007-12-27 2017-04-26 Infinity Pharmaceuticals, Inc. Métodos para reducción estereoselectiva
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
WO2010023480A1 (en) * 2008-08-29 2010-03-04 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Saturated bicyclic heterocyclic derivatives as smo antagonists
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
AU2010321773A1 (en) * 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3,3-二氟环丁烷甲酸的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
EP1474139B1 (en) 2002-02-01 2007-11-21 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
AU2004243301B2 (en) 2003-05-29 2010-03-25 Merck Sharp & Dohme Corp. Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
AU2005325267B2 (en) 2004-04-30 2010-11-04 Curis Inc. Quinoxaline inhibitors of the hedgehog signalling pathway
WO2006017542A1 (en) 2004-08-06 2006-02-16 Merck & Co., Inc. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP2316832B1 (en) 2004-08-27 2017-03-08 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
EP1789390B1 (en) 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
RU2007119637A (ru) 2004-10-28 2008-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов hedgehog-пути
NZ555419A (en) 2004-11-03 2009-07-31 Curis Inc Mediators of the hedgehog gene signaling pathways, compositions and uses related thereto
JP5036722B2 (ja) 2005-10-20 2012-09-26 メルク・シャープ・エンド・ドーム・コーポレイション 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1阻害剤としてのトリアゾール誘導体

Also Published As

Publication number Publication date
US7691887B2 (en) 2010-04-06
CL2008001074A1 (es) 2009-06-05
TW200901987A (en) 2009-01-16
ATE555785T1 (de) 2012-05-15
US20080262051A1 (en) 2008-10-23
AU2008241527A1 (en) 2008-10-30
EP2136803B1 (en) 2012-05-02
CA2683946C (en) 2013-01-22
EP2136803A1 (en) 2009-12-30
PE20090806A1 (es) 2009-06-27
JP5498936B2 (ja) 2014-05-21
JP2010524937A (ja) 2010-07-22
CN101663033B (zh) 2013-01-16
CN101663033A (zh) 2010-03-03
CA2683946A1 (en) 2008-10-30
WO2008130552A1 (en) 2008-10-30
AU2008241527B2 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
AR066063A1 (es) Derivados de triazol que son antagonistas de smo
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
MX2020008754A (es) Compuestos farmaceuticos.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
AR062391A1 (es) Uso de compuestos y derivados de 2,5 dihidroxibenceno para el tratamiento de dicracias hematologicas y cancer de un organo
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
UY30107A1 (es) Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
TN2010000038A1 (en) Organic compounds
UY30393A1 (es) Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR062737A1 (es) Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
PH12018500378A1 (en) Novel annelated phenoxyacetamides
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
MX2015012386A (es) Inhibidores de la cinasa cdk9.
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها

Legal Events

Date Code Title Description
FB Suspension of granting procedure